Cencora, Inc. $COR Shares Sold by Burney Co.

Burney Co. reduced its holdings in shares of Cencora, Inc. (NYSE:COR) by 10.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 90,245 shares of the company’s stock after selling 10,703 shares during the period. Cencora makes up 0.9% of Burney Co.’s investment portfolio, making the stock its 18th largest holding. Burney Co.’s holdings in Cencora were worth $28,204,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Atlantic Edge Private Wealth Management LLC grew its holdings in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares during the last quarter. Vermillion & White Wealth Management Group LLC lifted its position in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares during the period. Caldwell Trust Co acquired a new stake in Cencora during the 2nd quarter worth approximately $46,000. Capital A Wealth Management LLC grew its stake in shares of Cencora by 3,975.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after purchasing an additional 159 shares during the last quarter. Finally, Twin Peaks Wealth Advisors LLC acquired a new position in shares of Cencora in the second quarter valued at approximately $52,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 0.3%

Shares of NYSE COR opened at $341.12 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 52 week low of $223.92 and a 52 week high of $377.54. The firm has a 50-day moving average price of $348.66 and a 200 day moving average price of $314.86. The stock has a market capitalization of $66.17 billion, a price-to-earnings ratio of 42.91, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period last year, the company posted $3.34 earnings per share. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Insiders Place Their Bets

In related news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the transaction, the chief executive officer owned 68,059 shares of the company’s stock, valued at $23,374,863.55. This trade represents a 6.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 20,317 shares of company stock worth $7,009,260. 10.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on COR shares. Mizuho increased their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. TD Cowen lifted their target price on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Robert W. Baird set a $392.00 price target on shares of Cencora in a research note on Tuesday, December 16th. Finally, Wells Fargo & Company raised their price objective on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus price target of $373.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.